PFI-102

N/A

Report date: 2025/01/26 16:03:19

Base Information

Drug NamePFI-102
Drug Alias Nameanti-PAD4 mAbs (Pharma Foods/Yokohama City University/Nagoya City University)peptidyl arginine deiminase 4 mAbs (Pharma Foods/Yokohama City University/Nagoya City University)anti-PAD4 mAbs (Pharma Foods/Yokohama City University/Nagoya City University)PFI-102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProtein-arginine deiminase type-4 inhibitors
TargetsProtein-arginine deiminase type-4
Therapy Area/IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesYokohama City University
China Registration ClassN/A

Develop Information

Active CompaniesPharma Foods International Co LtdYokohama City UniversityNagoya City University
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A